Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Ultragenyx Pharmaceutical Inc. (RARE) had Receiveable Turnover of 1.12 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$136.00M |
|
$-185.00M |
|
$30.00M |
|
$106.00M |
|
$305.00M |
|
$-169.00M |
|
$-15.00M |
|
$-184.00M |
|
$-184.00M |
|
$-185.00M |
|
$-185.00M |
|
$-185.00M |
|
$-185.00M |
|
$-169.00M |
|
$-162.00M |
|
100.60M |
|
100.60M |
|
$-1.84 |
|
$-1.84 |
|
| Balance Sheet Financials | |
$657.00M |
|
$239.00M |
|
$639.00M |
|
$1.30B |
|
$325.00M |
|
-- |
|
$1.21B |
|
$1.53B |
|
$-236.00M |
|
$-454.00M |
|
$-236.00M |
|
98.30M |
|
| Cash Flow Statement Financials | |
$-197.00M |
|
$-49.00M |
|
-- |
|
$436.00M |
|
$189.00M |
|
$-247.00M |
|
$30.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
77.94% |
|
-124.26% |
|
-124.26% |
|
-- |
|
-135.29% |
|
-136.03% |
|
$-198.00M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
0.55 |
|
|
Receiveable Turnover |
1.12 |
80.07 |
|
78.39% |
|
40.75% |
|
-14.27% |
|
78.39% |
|
$-2.40 |
|
$-1.97 |
|
$-1.96 |
|